Relmada Therapeutics, Inc. (RLMD)
$3
+0.06 (+2.04%)
Rating:
Recommendation:
-
| Symbol | RLMD |
|---|---|
| Price | $3 |
| Beta | 0.078 |
| Volume Avg. | 0.15M |
| Market Cap | 90.298M |
| Shares () | - |
| 52 Week Range | 1.81-38.68 |
| 1y Target Est | - |
| DCF Unlevered | RLMD DCF -> | |
|---|---|---|
| DCF Levered | RLMD LDCF -> | |
| ROE | -93.51% | Strong Sell |
| ROA | -104.13% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -0.69 | |
| P/B | 0.81 | Buy |
Latest RLMD news
About
Download (Excel)Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
Healthcare
Biotechnology
NASDAQ Global Select
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.